TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Status:
Completed
Trial end date:
2016-03-21
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to confirm that at least 1 or more doses of telotristat
etiprate compared to placebo is effective in reducing the number of daily bowel movements
(BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the
trial in patients not adequately controlled by current SSA therapy.